Search Results
Oct 06, 2025, 09:00 ET Conexiant Partners with Greater New York Dental Meeting to Present 2025 Product Solutions Center
of Continuing Education in Dentistry, and Inside Dental Hygiene, Conexiant Dental is the largest producer of Continuing Dental Education (CDE) and offers a critical platform for dental professionals to access high-quality, trusted, and innovative content.
More news about: Conexiant
Sep 23, 2025, 10:00 ET NEW YORK CITY REGIONAL CENTER-MANAGED ENTITY PROVIDES FUNDING FOR 11TH CHARTER SCHOOL IN NEW YORK CITY
Treasury to NYCR-CDE, a Community Development Entity managed by New York City Regional Center. To receive a New Market Tax Credit allocation award, NYCR-CDE was required to demonstrate a mission and track record of providing investment capital for low-income communities. Since 2016, NYCR-CDE has received
More news about: New York City Regional Center
Sep 23, 2025, 04:57 ET Kelun-Biotech to Present Results from Multiple Clinical Studies at the 2025 ESMO Congress
for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in January 2025 for the treatment of adult patients with HER2+ unresectable or metastatic BC who have received at least one prior anti-HER2 therapy was accepted by the CDE of the NMPA. At a pre-specified
More news about: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Sep 22, 2025, 22:56 ET Ivonescimab HARMONi-6 Results Selected for ESMO 2025 LBA; Final Phase III Results of Cadonilimab as First-Line Therapy for Advanced Gastric Cancer to Be Published as an Oral Presentation
across all subgroups, regardless of PD-L1 expression status. On July 28, 2025, the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) accepted the supplemental New Drug Application (sNDA) for ivonescimab in combination with chemotherapy
More news about: Akeso, Inc.
Sep 22, 2025, 22:16 ET Kelun-Biotech's New Drug Application for Its Novel Next-generation Selective RET Inhibitor A400/EP0031 Accepted for Review by the NMPA for the Treatment of RET-fusion positive NSCLC
molecule rearranged during transfection (RET) kinase inhibitor A400 (also known as EP0031) was accepted for review by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China for the treatment of adult patients with RET-fusion
More news about: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.